Armata’s therapeutic phage candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing.
| Pathogen / Indication | Discovery | Preclinical | IND-Enabling | CMC | Phase 1b/2 | Partner |
|---|---|---|---|---|---|---|
| Pseudomonas aeruginosa | ||||||
| CF Lung Infections |  |
|||||
| Pneumonia | ||||||
| Staphylococcus aureus | ||||||
| Bacteremia | US DoD* |
| Phage Candidate | Pathogen & Indication |
Phase | Partner | |||||
|---|---|---|---|---|---|---|---|---|
| AP-PA02 |
|
|||||||
| AP-SA02 | S. aureus Bacteremia |
Phase 1b/2 (2021) | US DoD* | |||||
SWARM-P.a. NCT Number; NCT04596319; Cystic Fibrosis Foundation TrialFinder
*Department of Defense (Naval Medical Research Center, US Army Medical Research Acquisition Activity, Defense Health Agency)
| Discovery-Stage | |
|---|---|
| Engineered Phage undisclosed target/indication |  |
| Escherichia coli Klebsiella pneumoniae |
| Discovery-Stage | |
|---|---|
| Engineered Phage undisclosed | |
| Escherichia coli Klebsiella pneumoniae |
